William Blair reaffirmed their outperform rating on shares of Five9 (NASDAQ:FIVN – Free Report) in a research note issued to investors on Thursday,RTT News reports. Other equities analysts have also ...

Equities research analysts at William Blair issued their FY2029 earnings per share (EPS) estimates for shares of Genmab A/S ...

William Blair downgraded Udemy (UDMY) to Market Perform from Outperform after the company announced the appointment of Hugo Sarrazin as ...

JPMorgan Chase & Co. has hired William Kallop from William Blair & Co. for its mergers and acquisitions group focused on ...

Fintel reports that on March 12, 2025, William Blair downgraded their outlook for Udemy (NasdaqGS:UDMY) from Outperform to ...

The firm upgraded Palantir from Underperform to Market Perform after a sharp stock decline but did not assign a price target.

Fintel reports that on March 11, 2025, William Blair upgraded their outlook for Genmab A (NasdaqGS:GMAB) from Market Perform ...

Autism software provider CentralReach has been looking for a potential buyer, according to multiple sources with knowledge of ...

Palantir shares surged Wednesday as William Blair analysts suggested the company’s software could be well positioned to ...

William Blair analyst Andy Hsieh reiterated a Hold rating on Nektar Therapeutics (NKTR – Research Report) today. The company’s shares closed ...

The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...

The note emphasized that Palantir shares declined 10% following a 4% selloff in the Nasdaq, and if the broader market ...